News

Richmond-based manufacturer expands operations to reduce waste, pollution and cost in the laboratory industry

Seven years after its founding as a startup business in Richmond, Grenova Inc. has moved into a new phase of development as a company.

“We have been growing quite significantly,” said Ali Safavi, the founder and CEO of Grenova, which has a mission to reduce waste, pollution and costs in the global laboratory industry. Grenova, which stands for Green Innovation, announced plans in April to relocate its operations from a 10,000-square-foot facility in the Manchester area of South Richmond to a 35,000-square-foot building at 1900 Ellen Road just north of Scott’s Addition. The company also announced plans to invest $10.6 million to expand its production and hire 250 people over the next three years. The newly renovated facility – formerly occupied by Sampson Coatings Inc. – is now operating as Grenova’s main office, research and development and manufacturing facility, with more than 60 employees.

Grenova designs and manufactures equipment that health care businesses, universities and government agencies can install in their laboratories to wash and sterilize plastic pipette tips, the small tools used to transfer samples in medical diagnostic tests and research projects such as drug development. Grenova’s goal from the start has been to reduce the billions of pounds of plastic pipette tips that are discarded after one use and end up in landfills.

“About every two and half years, we have tripled our footprint,” said Safavi, noting that the company started in 2014 in a 3,200 square foot office in Midlothian before moving to Manchester and now to the site on Ellen Road. At the new facility, the company can make up to 2,800 cleaning and sterilization units per year, per work shift, Safavi said. That’s up from a capacity of just a few hundred units at its previous location.

To learn more please visit Richmond Times-Dispatch

Recent News

02/20/2025

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

“Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return

02/11/2025

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,  announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration seeks to develop the first intranasal therapy for mild traumatic brain injury (mTBI) aka concussion, creating a comprehensive trigger-to-treat

02/11/2025

Children’s National and Compremium partner on pediatric medtech innovation

Children’s National Hospital announced a new collaboration with Swiss medical device company Compremium AG to co-develop and commercialize innovative medical technologies designed specifically for pediatric patients. This first-of-its-kind agreement leverages the expertise of Children’s National in pediatric healthcare innovation and Compremium’s non-invasive platform technology for diagnosing pressure-related conditions, accelerating advancements in pediatric medicine. Diagnosing pressure-related